Biotech was the largest subsector by value with 42 deals worth $38.8 billion
Mergermarket has released its global Pharma, Medical & Biotech (PMB) trend report for the first quarter (Q1) of 2017. Global M&A in the PMB sector saw 314 deals worth $76 billion in the first quarter, representing a 14.8 per cent decrease in value with 65 fewer deals compared to Q1 2016 (379 deals, $89.2 billion). PMB’s total value also accounted for an 11 per cent market share of global M&A. Although the market share was less than the 14.3 per cent achieved in Q1 2016, Q2 2016 ($83.9 billion), Q3 2016 ($57.1 billion), and Q4 2016 ($ 59.3 billion) had seen 11.1 per cent, 6.4 per cent, and 5.9 per cent, respectively. Therefore, Q1 2017 was either on par or greater than the last three quarters.
Biotech was the largest subsector by value with 42 deals worth $38.8 billion, an increase in value of 1,021.7 .per cent compared to Q1 2016 (48 deals, $3.5 billion). This is the largest quarterly value that biotech has achieved since Q1 2009 ($44.7 billion).
The Asia-Pacific region (excluding Japan) had the lowest amount of PMB M&A by value, with 56 deals worth $4.1 billion. This was a decrease of 47.4 per cent with nine fewer deals compared to Q1 2016 (65 deals, $7.9 billion).